Translational Bioengineering for Regenerative Applications

Section: Biotechnology & Bioengineering

Why This Special Issue?

Advances in bioengineering are rapidly transforming the field of regenerative medicine. As the global burden of chronic disease, tissue degeneration, and organ failure continues to rise, innovative strategies are needed to repair, regenerate, or replace damaged tissues and biological systems.

Translational bioengineering integrates engineering principles, molecular biology, biomaterials science, and clinical medicine to bridge the gap between laboratory discoveries and therapeutic applications. Recent breakthroughs in stem cell engineering, gene modulation technologies, biomimetic scaffolds, and bioactive materials are enabling the development of next-generation regenerative therapies.

Modern regenerative approaches increasingly combine multiple technological platforms, including:

• Biomimetic scaffold design and tissue engineering systems
• Stem cell bioengineering and cellular reprogramming
• Precision gene modulation using CRISPR-based technologies
• Epigenome editing and RNA-targeting platforms
• Bioactive materials and regenerative biomaterials
• Controlled molecular signaling for tissue repair and regeneration

These interdisciplinary advances are reshaping regenerative medicine and creating new opportunities for translational therapies capable of addressing previously untreatable conditions.

Aim & Scope of This Special Issue

Regenerative medicine is evolving into a highly interdisciplinary field where bioengineering innovations translate fundamental biological discoveries into clinical therapies. This Special Issue focuses on the development of translational bioengineering technologies that enable tissue regeneration, cellular repair, and therapeutic reconstruction of biological systems.

We seek high-quality research that bridges biomaterials science, stem cell engineering, gene regulation technologies, and clinical translation to accelerate the development of regenerative solutions. Submissions are encouraged from researchers working at the intersection of bioengineering, molecular biology, regenerative medicine, and translational biotechnology.

Topics of Interest Include (but are not limited to)

• Biomimetic scaffold design for tissue repair and regeneration
• Tissue engineering platforms and regenerative biomaterials
• Stem cell bioengineering and cellular reprogramming technologies
• Regenerative scaffolds and bioactive materials for therapeutic applications
• CRISPRa/i-based gene activation and repression systems
• Epigenome editing for cellular reprogramming and regenerative pathways
• RNA-targeting technologies for gene modulation and therapeutic control
• Controlled gene regulation strategies for regenerative medicine
• Bioengineered microenvironments and tissue niche engineering
• Therapeutic biomimicry and biologically inspired regenerative systems
• Translational bioengineering approaches for clinical regenerative therapies

Lead Guest Editor & Welcome Note

Lead Guest Editor: To be appointed soon.

The Lead Guest Editor will provide academic oversight for the Special Issue, ensuring thematic coherence, scientific rigor, and alignment with the editorial standards of IgMin Research – A BioMed & Engineering Open Access Journal. The appointment will be formally announced upon completion of the editorial board review process.

Co-Guest Editor

Wanderson Gabriel Gomes de Melo, MSc
PhD Student in Health Biotechnology
Rede Nordeste de Biotecnologia (Renorbio)
Universidade Federal do Piauí (UFPI), Brazil
Email: [email protected]
ORCID: 0000-0002-5120-2281

Research Focus

Tissue repair and regenerative biology, stem cell–microenvironment interactions, biomaterial-guided cellular modulation, mitochondrial regulation of cell fate, and computational transcriptomic modeling of gene regulatory networks in renal pathophysiology.

Academic Background

• PhD Student in Health Biotechnology, Renorbio – UFPI (CAPES Fellow)
• MSc in Cellular Biotechnology and Applications, UFPI
• BSc in Veterinary Medicine, UFPI

Research Expertise

His research integrates experimental regenerative bioengineering and computational systems biology, including:

• Mesenchymal stem cell culture and biomaterial–cell interactions
• Development of bioactive hydrogels and composite scaffolds for tissue engineering
• RNA-seq data integration and gene regulatory network modeling
• Network pharmacology and machine learning approaches for molecular pathway discovery

Selected Publications

• Melo WGG et al. GLP-1 and diabetic nephropathy share key molecular targets. Canadian Journal of Physiology and Pharmacology (2026).
• Melo WGG et al. Behavioral dynamics of medicinal signaling cells from porcine bone marrow. Canadian Journal of Physiology and Pharmacology (2024).
• Da Silva MH et al. Titanate nanotube heterojunction enhanced by curcumin. Colloids and Surfaces A (2025).
• Vieira de Sousa TW et al. Composite scaffolds for bone tissue engineering. ACS Omega (2025).
• Reis FS et al. Buriti oil-based scaffold development. ACS Omega (2025).

Editorial Role
As Co-Guest Editor, Dr. Melo contributes expertise in biomaterial-guided regeneration, stem cell bioengineering, and computational transcriptomics, supporting the evaluation of submissions related to translational regenerative technologies and bioengineered therapeutic platforms.

Manuscript Submission & Guidelines

Submissions Open
Final Submission Deadline: August 31, 2026

Submission Portal: https://www.igminresearch.com/submission

Continuous Publication Model

Accepted manuscripts are published immediately upon final acceptance in the regular journal volume and are permanently linked to this Special Issue collection. Authors may optionally submit a 250-word abstract for pre-submission feedback to confirm scope alignment.

Article Types Accepted

• Original Research
• Review Articles
• Systematic Reviews
• Perspectives
• Short Communications
• Commentaries and related article types

Publication Timeline & Editorial Process

Manuscript Submission Window
March 1, 2026 – August 31, 2026

Editorial Workflow Timeline (per manuscript)

• Initial Editorial Screening: Within 2–3 days of submission
• First Peer Review Decision: Within 2 weeks of submission
• Author Revision Period: 2–3 weeks depending on revision type
• Second Review (if required): 2 weeks
• Final Decision: Within 7 days of revised submission
• Online Publication: 10–14 days after final acceptance

Estimated total time from submission to publication: 5–6 weeks.

Frequently Asked Questions (FAQ's)

Can I submit a manuscript slightly outside the listed themes?
If your work broadly aligns with the scope of this Special Issue, you are encouraged to submit. Authors may also contact the editorial office with a brief abstract for preliminary feedback.

What happens if I miss the final submission deadline?
Manuscripts received after the deadline may be considered for publication in the regular journal section.

Is the APC charged if my manuscript is rejected?
No. APCs apply only to manuscripts that are accepted following peer review.

Can Guest Editors submit manuscripts to this issue?
Yes. Guest Editors may submit manuscripts; however, they must recuse themselves from the editorial handling of their own submissions. Final decisions are made by the Section Editors or delegated editorial board members.

Editorial & Ethical Statement

All manuscripts submitted to this Special Issue must align with the scope of IgMin Research – A BioMed & Engineering Open Access Journal and adhere to the journal’s ethical standards regarding authorship, originality, data transparency, and competing interests.

The journal follows internationally recognized publication ethics guidelines including those established by the Committee on Publication Ethics (COPE) and related best-practice editorial standards. All manuscripts undergo independent peer review, and the final decision on publication rests solely with the Section Editors.